(:IMMU)

Business Focus: N/A

Nov 27, 2020 08:00 am ET

Portnoy Law Firm: Tactile Systems Technology, Inc., Pintec Technologies Holdings Limited, and Immunomedics, Inc. Investors Have Limited Amount of Time Before Class Action Deadline

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated...

Oct 12, 2020 08:00 am ET

Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products Development of the U.S. Food and Drug...

Oct 01, 2020 11:35 am ET

Moore Kuehn Encourages IMMU, MOBL, MR, and SCBH Investors to Contact Law Firm

Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek...

Sep 22, 2020 03:00 pm ET

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of IMMU, VRTU, RST, and CBMG Buyouts

Rigrodsky & Long, P.A. announces that it is investigating: Immunomedics, Inc. (NASDAQ GS: IMMU) regarding possible breaches of fiduciary duties and other violations of law related to Immunomedics’ agreement to be acquired by Gilead Sciences, Inc....

Sep 21, 2020 10:00 am ET

MERGER ALERT – SBPH, IMMU, and MNTA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

NEW YORK, NY / ACCESSWIRE / September 21, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:

Sep 19, 2020 11:00 am ET

Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced positive results from cohort 1 of cisplatin-eligible patients in the pivotal Phase 2...

Sep 19, 2020 10:30 am ET

Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that results from the confirmatory Phase 3 ASCENT study showed that Trodelvy...

Sep 18, 2020 08:00 am ET

Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Trodelvy delivered 150-fold and 40-fold the 50% inhibitory concentration (IC50)...

Sep 17, 2020 02:45 pm ET

MERGER ALERT – MFAC, IMMU, and MKGI: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

NEW YORK, NY / ACCESSWIRE / September 17, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:

Sep 16, 2020 01:29 pm ET

Lifshitz Law Firm, P.C. Announces Investigation of Immunomedics, Inc. (NASDAQ: IMMU), Livongo Health, Inc. (NASDAQ:LVGO), Varian Medical Systems, Inc. (NYSE: VAR) and Virtusa Corporation (NASDAQ: VRTU

Immunomedics, Inc. (NASDAQ: IMMU) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of Immunomedics to Gilead Sciences, Inc. for $88.00 per share in cash. If you are a IMMU...

Sep 14, 2020 02:57 pm ET

IMMUNOMEDICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Immunomedics - IMMU

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Immunomedics (NasdaqGS: IMMU) to Gilead Sciences, Inc. (NasdaqGS: GILD). Under the terms of the proposed transaction, shareholders of Immunomedics will receive only $88.00 in cash for each share of Immunomedics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Sep 14, 2020 01:59 pm ET

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Immunomedics, Inc. Buyout

Rigrodsky & Long, P.A. announces that it is investigating Immunomedics, Inc. (“Immunomedics”) (NASDAQ GS: IMMU) regarding possible breaches of fiduciary duties and other violations of law related to Immunomedics’ agreement to be acquired by Gilead...

Sep 13, 2020 10:00 pm ET

Immunomedics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Immunomedics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – IMMU

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Immunomedics, Inc. (NASDAQ: IMMU) to Gilead Sciences, Inc. for $88.00 per share is fair to Immunomedics shareholders.

Sep 13, 2020 03:00 pm ET

Gilead Sciences to Acquire Immunomedics

Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Boards of Directors and is anticipated to close during the fourth quarter of 2020.

Sep 09, 2020 07:00 am ET

Immunomedics Announces Key Oral Presentations at ESMO Virtual Congress 2020

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the presentation of five abstracts at ESMO Virtual Congress 2020, highlighted by oral...

Sep 02, 2020 08:00 am ET

Immunomedics to Participate in Upcoming Healthcare Conferences

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual...

Aug 17, 2020 08:00 am ET

Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer for Trodelvy™

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval...

Aug 05, 2020 04:00 pm ET

Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today reported financial results for the second quarter of 2020. Please refer to the Company’s...

Jul 27, 2020 08:00 am ET

Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 2020

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Wednesday, August 5, 2020 at 5:00 p.m. Eastern...

Jul 13, 2020 04:00 pm ET

Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced an extension of its current clinical collaboration with Roche to evaluate...

Jul 09, 2020 03:55 pm ET

Lifshitz Law Firm, P.C. Announces Investigation of Acer Therapeutics, Inc. (ACER), Advanced Disposal Services, Inc. (ADSW), Apyx Medical Corporation (APYX), Honeywell International Inc. (HON), Immunom

NEW YORK, July 9, 2020 /PRNewswire/ --

Jul 06, 2020 07:55 am ET

Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™ in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the confirmatory Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy)...

Jul 02, 2020 04:05 pm ET

Immunomedics to Host Conference Call and Webcast on July 6, 2020 to Provide Clinical Update

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Company will host a conference call and live audio webcast on Monday, July 6,...

Jun 29, 2020 04:25 pm ET

Shareholder Alert: Robbins LLP Announces It Is Investigating Immunomedics, Inc. (IMMU) for Misleading Shareholders

Shareholder rights law firm Robbins LLP announces that it is investigating Immunomedics, Inc. (NASDAQ: IMMU) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Immunomedics, a clinical-stage biopharmaceutical company,

Jun 24, 2020 06:01 pm ET

Shareholder Alert: Robbins LLP Reminds Investors Shareholder Class Action Against Immunomedics, Inc. (IMMU) Survives Motion to Dismiss

Shareholder rights law firm Robbins LLP reminds investors that purchasers of Immunomedics, Inc. (NASDAQ: IMMU) filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1934 between April 20, 2016 and June 2, 2016. Immunomedics, a clinical-stage biopharmaceutical company, foc

Jun 05, 2020 05:33 pm ET

Lifshitz Law Firm, P.C. Announces Investigation of Apyx Medical Corporation (APYX), Honeywell International Inc. (HON), Immunomedics, Inc. (IMMU), and Zuora, Inc. (ZUO)

Apyx Medical Corporation (APYX) Lifshitz Law Firm, P.C. announces investigation into possible breaches of fiduciary duty by certain of Apyx’s officers and/or directors. The investigation relates to a securities class action lawsuit alleging...

Jun 02, 2020 06:34 pm ET

Shareholder Alert: Robbins LLP Announces Shareholder Class Action Against Immunomedics, Inc. (IMMU) Survives Motion to Dismiss

May 28, 2020 08:00 am ET

Immunomedics to Participate in Upcoming Healthcare Conferences

May 27, 2020 04:00 pm ET

Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today provided a business update on a leadership change as well as the Company’s efforts to navigate...

May 13, 2020 05:01 pm ET

Immunomedics to Present New Trodelvy™ Data In Non-Breast Cancer Indications at the 2020 ASCO Virtual Meeting

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that its recently FDA-approved ADC, Trodelvy, showed clinical activity in...

May 07, 2020 08:00 am ET

Immunomedics to Participate in BofA Securities 2020 Health Care Conference

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in a...

May 06, 2020 04:00 pm ET

Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today reported financial results for the first quarter of 2020. Please refer to the Company’s...

May 06, 2020 09:31 am ET

Thinking about trading stocks or options in Beyond Meat, Horizon Therapeutics, Overstock.com, Peloton, or Immunomedics?

NEW YORK, May 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BYND, HZNP, OSTK, PTON, and IMMU.

May 04, 2020 08:00 am ET

Immunomedics Announces Commercial Availability of TRODELVY™ in the United States

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Trodelvy (sacituzumab govitecan-hziy) is now available through major...

May 01, 2020 04:05 pm ET

Immunomedics Announces Closing Of Public Offering Of Common Stock

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the closing of its previously announced underwritten public offering of common stock....

Apr 30, 2020 09:31 am ET

Thinking about trading stocks or options in Tesla, Immunomedics, Mastercard, Micron Technology, or ServiceNow?

NEW YORK, April 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, IMMU, MA, MU, and NOW.

Apr 30, 2020 08:00 am ET

Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast On May 6, 2020

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Wednesday, May 6, 2020 at 5:00 p.m. Eastern...

Apr 28, 2020 11:50 pm ET

Immunomedics Announces Pricing of Public Offering of Common Stock

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the pricing of an underwritten public offering of 14,736,860 shares of its common...

Apr 27, 2020 04:01 pm ET

Immunomedics Announces Proposed Public Offering Of Common Stock

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced it has commenced an underwritten public offering of $350,000,000 of shares of its...

Apr 24, 2020 09:15 pm ET

CORRECTION: Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Nega

In a release issued under the same headline on Friday, April 24th by Everest Medicines (Nasdaq: IMMU), at the end of the subheading, please note that it should read as “breast cancer”, not “break cancer”. The corrected release follows: Everest...

Apr 24, 2020 07:00 am ET

Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that...

Apr 23, 2020 09:31 am ET

Thinking about buying stock in Chesapeake Energy Corp, General Electric, Immunomedics, TOP Ships, or United Airlines?

NEW YORK, April 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHK, GE, IMMU, TOPS, and UAL.

Apr 23, 2020 08:00 am ET

Multimedia Update: FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer

Apr 22, 2020 11:47 am ET

FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer

Apr 07, 2020 09:28 am ET

CORRECTION - FDA GRANTS FAST TRACK DESIGNATION TO SACITUZUMAB GOVITECAN FOR LOCALLY-ADVANCED OR METASTATIC UROTHELIAL CANCER

In a release issued earlier today by Immunomedics, Inc. (Nasdaq:IMMU), the headline was inaccurate. The cancer is accurately described as locally-advanced or metastatic, not neoadjuvant/adjuvant metastatic. The corrected headline appears above. The...

Apr 07, 2020 08:00 am ET

FDA GRANTS FAST TRACK DESIGNATION TO SACITUZUMAB GOVITECAN FOR NEOADJUVANT/ADJUVANT METASTATIC UROTHELIAL CANCER

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation...

Apr 06, 2020 08:00 am ET

IMMUNOMEDICS ANNOUNCES ASCENT STUDY TO BE STOPPED FOR COMPELLING EFFICACY

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that its Phase 3 confirmatory ASCENT study will be halted due to compelling evidence...

Apr 06, 2020 07:50 am ET

IMMUNOMEDICS ANNOUNCES EXECUTIVE LEADERSHIP CHANGES AND THE APPOINTMENT OF HAROUT SEMERJIAN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that its Board of Directors (Board) has appointed Harout Semerjian as President and...

Apr 03, 2020 05:00 pm ET

IMMUNOMEDICS TO HOST CONFERENCE CALL AND WEBCAST ON APRIL 6, 2020 TO PROVIDE CLINICAL AND CORPORATE UPDATE

Mar 25, 2020 08:00 am ET

IMMUNOMEDICS PROVIDES COVID-19 BUSINESS CONTINUITY UPDATE, AFFIRMS 2020 STRATEGIC PRIORITIES, AND SHARES R&D AND REGULATORY UPDATE

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today provided a business update in lieu of the changes brought upon by the novel coronavirus...

Feb 27, 2020 04:10 pm ET

Immunomedics Appoints Robert W. Azelby to Board of Directors

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADCs), today announced the appointment of Robert W. Azelby to the Company’s board of directors. Mr....

Feb 27, 2020 04:00 pm ET

Immunomedics Reports Fourth Quarter and Full Year 2019 Results and Provides Corporate Update

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today reported financial results for the fourth quarter and full year 2019. Please refer to the...

Feb 25, 2020 08:00 am ET

Immunomedics to Participate in Upcoming Healthcare Conferences

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Company will participate in fireside chats at the following healthcare...

Feb 20, 2020 08:00 am ET

Immunomedics to Report Results for the Fourth Quarter and Full Year 2019 and Host Conference Call and Webcast on February 27, 2020

Feb 14, 2020 08:00 am ET

Immunomedics Appoints Dr. Loretta Itri Chief Medical Officer

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the appointment of Loretta Itri, M.D. as chief medical officer (CMO), effective today....

Feb 06, 2020 08:00 am ET

Immunomedics to Participate in Guggenheim Healthcare Talks | Oncology Day

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, executive chairman, is scheduled to participate in a...

Dec 26, 2019 08:00 am ET

Immunomedics Announces FDA Acceptance for Filing of Biologics License Application Resubmission for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer

Dec 09, 2019 04:01 pm ET

Immunomedics Announces Closing of Public Offering of Common Stock

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the closing of its previously announced underwritten public offering of common...

Dec 04, 2019 08:29 pm ET

Immunomedics Announces Pricing of Public Offering of Common Stock

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the pricing of an underwritten public offering of 14,285,715 shares of its...

Dec 03, 2019 04:01 pm ET

Immunomedics Announces Proposed Public Offering of Common Stock

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced it has commenced an underwritten public offering of $250,000,000 of shares of...

Dec 03, 2019 08:00 am ET

Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and...

Nov 13, 2019 08:00 am ET

Immunomedics to Present at Upcoming Healthcare Conferences

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to present at the...

Oct 30, 2019 04:00 pm ET

Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today reported financial results for the third quarter of 2019. Please refer to the Company’s...

Oct 23, 2019 08:00 am ET

Immunomedics to Report Third Quarter 2019 Results and Host Conference Call and Webcast on October 30, 2019

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Wednesday, October 30, 2019 at 5:00 p.m....

Oct 04, 2019 10:00 pm ET

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm

Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, In. (NASDAQ: HCSG), Heron Therapeutics, Inc. (NASDAQ: HRTX), Immunomedics, Inc. (NASDAQ: IMMU), and Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) on...

Oct 01, 2019 08:00 am ET

Immunomedics to Present at the 2019 Cantor Global Healthcare Conference

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to present at the...

Sep 28, 2019 12:30 pm ET

Immunomedics Provides Corporate Update

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today presented at the European Society for Medical Oncology (ESMO) Annual Congress interim data...

Sep 12, 2019 08:00 am ET

Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host an Investor Event on Saturday, September 28, 2019 at 6:30 p.m....

Sep 05, 2019 07:53 pm ET

Bragar Eagel & Squire is Investigating Certain Officers and Directors of MGT Capital Investments, First American Financial, Immunomedics, and AAC Holdings and Encourages Investors to Contact the Firm

Bragar Eagel & Squire is investigating certain officers and directors of MGT Capital Investments (Other OTC: MGTI), First American Financial Corporation (NYSE: FAF), Immunomedics, Inc. (NASDAQ: IMMU), and AAC Holdings, Inc. (NYSE: AAC) on behalf of...

Sep 04, 2019 07:45 am ET

Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that its TROPHY-U-01 late-breaking abstract on interim results of sacituzumab...

Sep 03, 2019 02:58 pm ET

Shareholder Alert: Robbins Arroyo LLP Reminds Investors Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP reminds investors that purchasers of Immunomedics, Inc. (NASDAQGM: IMMU) filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1934 between August 23, 2018 and December 20, 2018. Immunomedics, a clinical-stage biopharmaceutical comp

Aug 28, 2019 08:00 am ET

Immunomedics to Participate in Upcoming Healthcare Conferences

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate in fireside chats at the following healthcare...

Aug 07, 2019 04:00 pm ET

Immunomedics Reports Second Quarter 2019 Results and Provides Corporate Update

Aug 01, 2019 08:00 am ET

Immunomedics to Report Second Quarter 2019 Results and Host Conference Call and Webcast on August 7, 2019

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Wednesday, August 7, 2019 at 5:00 p.m....

May 29, 2019 08:00 am ET

Immunomedics to Participate in Upcoming Healthcare Conferences

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate in fireside chats at the following healthcare...

May 09, 2019 07:00 am ET

Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update

May 07, 2019 08:00 am ET

Immunomedics To Participate In Upcoming Healthcare Conferences

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate in fireside chats at the following healthcare...

May 02, 2019 08:00 am ET

Immunomedics to Report First Quarter 2019 Results and Host Conference Call and Webcast on May 9, 2019

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Thursday, May 9, 2019 at 8:00 a.m....

Apr 29, 2019 07:40 am ET

Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC) and Everest Medicines II Limited (“Everest Medicines”), a C-Bridge Capital-backed...

Apr 29, 2019 07:35 am ET

Immunomedics Announces Departure of Chief Medical Officer

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Rob Iannone, M.D., has decided to leave the Company to pursue a career...

Apr 08, 2019 09:00 am ET

Immunomedics Announces Promotion Agreement With Janssen for Erdafitinib in the U.S.

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it has entered into a promotion agreement in which Immunomedics will...

Mar 07, 2019 04:01 pm ET

Immunomedics Appoints Barbara G. Duncan to Board of Directors

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the appointment of Barbara G. Duncan to the Company’s Board of Directors and as...

Mar 04, 2019 08:00 am ET

Immunomedics to Participate in Cowen and Company 39th Annual Health Care Conference

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate in a fireside chat at Cowen and Company 39th...

Mar 01, 2019 08:35 am ET

Research Report Identifies Axalta Coating, The Home Depot, Immunomedics, Kosmos Energy, Casa, and Ormat Technologies with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Axalta Coating Systems Ltd. (NYSE:AXTA), The Home Depot, Inc. (NYSE:HD),...

Feb 26, 2019 08:30 am ET

Lawsuit for Investors in NASDAQ: IMMU shares against Immunomedics, Inc. announced by Shareholders Foundation

The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: IMMU shares over alleged securities laws violations by Immunomedics, Inc. Investors, who purchased shares of Immunomedics, Inc. (NASDAQ: IMMU),...

Feb 25, 2019 05:54 pm ET

CLASS ACTION UPDATE for IMMU, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...

Feb 25, 2019 04:01 pm ET

Immunomedics Reports Results For Period Ended December 31, 2018, Strengthens Board And Announces Senior Leadership Changes

Feb 25, 2019 03:16 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DNKEY, IMMU, PRGO and DXC

The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...

Feb 25, 2019 02:19 pm ET

CLASS ACTION UPDATE for IMMU, DXC and W: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 25, 2019 12:30 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of IMMU, YRIV, MAXR and SVXY

Feb 24, 2019 10:50 pm ET

IMMUNOMEDICS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Immunomedics, Inc. - IMM

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until February 25, 2019 to file lead plaintiff applications in a securities class action lawsuit against Immunomedics, Inc. (NasdaqGM: IMMU). Investor losses must relate to purchases of the Company’s shares between the expanded period of February 8, 2018 and January 18, 2019. This action is pending in the United States District Court for the District of New Jersey.

Feb 24, 2019 06:06 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC Technology, Immunomedics, Natural Health, and Maiden Holdings and Encourages Investors to Contact t

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of DXC Technology Company, Immunomedics, Inc., Natural Health Trends Corp., and Maiden Holdings, Ltd. Stockholders have until the...

Feb 24, 2019 01:57 pm ET

CLASS ACTION UPDATE for SOGO, IMMU, W and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 24, 2019 10:55 am ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ARLO, IMMU, MKL and SVXY

Feb 22, 2019 10:50 pm ET

Immunomedics 72 Hour Deadline Alert: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until February 25, 2019 to file lead plaintiff applications in a securities class action lawsuit against Immunomedics, Inc. (NasdaqGM: IMMU). Investor losses must relate to purchases of the Company’s shares between the expanded period of February 8, 2018 and January 18, 2019. This action is pending in the United States District Court for the District of New Jers

Feb 22, 2019 05:27 pm ET

CLASS ACTION UPDATE for IMMU, GSM, TYME and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 22, 2019 01:54 pm ET

CLASS ACTION UPDATE for YRCW, IMMU, MKL and MAXR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 22, 2019 01:07 pm ET

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Immunomedics, Inc.

Law Offices of Howard G. Smith reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU)...

Feb 22, 2019 12:35 pm ET

DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunomedics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunomedics, Inc. (“Immunomedics” or “the Company”) (NASDAQ: IMMU) for violations of §§10(b) and 20(a) of the Securities...

Feb 22, 2019 11:13 am ET

CLASS ACTION UPDATE for IMMU, ALKS, UXIN and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 21, 2019 07:00 pm ET

CLASS ACTION UPDATE for YRCW, IMMU, W and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 21, 2019 04:57 pm ET

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Immunomedics, Inc. (IMMU)

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ:...

Feb 21, 2019 02:13 pm ET

CLASS ACTION UPDATE for IMMU, MKL, ATVI and BRS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 21, 2019 11:53 am ET

CLASS ACTION UPDATE for IMMU, DBVT, DXC and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 20, 2019 07:50 pm ET

CLASS ACTION UPDATE for ARLO, SOGO, IMMU and DXC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 20, 2019 05:25 pm ET

KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for IMMUNOMEDICS, INC. Investors – IMMU

Feb 20, 2019 05:05 pm ET

Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that updated data from the Phase 2 study of sacituzumab govitecan in patients...

Feb 20, 2019 05:00 pm ET

IMMU UPCOMING FEBRUARY 25th DEADLINE: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Important Deadline in Securities Class Action Lawsuit; Expanded Class Period – IMMU

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Immunomedics, Inc. (NASDAQ: IMMU) from February 8, 2018 through January 18, 2019, inclusive (the “Class Period”) of the important February 25, 2019 lead...

Feb 20, 2019 04:22 pm ET

Block & Leviton LLP Reminds Shareholders of Important Deadlines; IMMU, PRGO, YRC, W

Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important deadlines listed below. If you have purchased or otherwise acquired any of the securities listed below,...

Feb 20, 2019 02:21 pm ET

CLASS ACTION UPDATE for IMMU, DBVT, YRIV and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 20, 2019 11:54 am ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of YRCW, IMMU, W and AVP

Feb 20, 2019 09:52 am ET

CLASS ACTION UPDATE for IMMU, AXGN, ATVI and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 19, 2019 02:17 pm ET

Block & Leviton LLP Reminds Shareholders of Important Deadlines; IMMU, PRGO, YRC, NHTC

Feb 19, 2019 01:36 pm ET

CLASS ACTION UPDATE for SOGO, IMMU, GSM and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 19, 2019 12:27 pm ET

February 25th Immunomedics (NASDAQ: IMMU) Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against Immunomedics, Inc. – IMM

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the important February 25, 2019 lead plaintiff deadline in the shareholder class action lawsuit against Immunomedics, Inc. (“Immunomedics” or the...

Feb 19, 2019 11:33 am ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DNKEY, GS, IMMU and MAXR

Feb 19, 2019 10:33 am ET

CLASS ACTION UPDATE for IMMU, PRGO, ALKS and VALE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 19, 2019 10:00 am ET

Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) and DXC Technology Company (DXC) and YRC Worldwide Inc. (YRCW): Bronstein, Gewirtz & Grossman, LLC Class Action Update

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

Feb 19, 2019 08:00 am ET

Immunomedics to Report Results for the Quarter and Six Months Ended December 31, 2018 and Host Conference Call and Webcast on February 25, 2019

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Monday, February 25, 2019 at 5:00 p.m....

Feb 18, 2019 02:00 pm ET

CLASS ACTION UPDATE for IMMU, DBVT, ATVI and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 18, 2019 10:03 am ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DNKEY, GS, IMMU and MAXR

Feb 18, 2019 07:18 am ET

CLASS ACTION UPDATE for YRCW, IMMU, MKL and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 17, 2019 02:05 pm ET

CLASS ACTION UPDATE for IMMU, DBVT, MU and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 17, 2019 02:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NVIDIA, DXC Technology, Immunomedics, and Natural Health and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of NVIDIA Corporation, DXC Technology Company, Immunomedics, Inc., and Natural Health Trends Corp. Stockholders have until the...

Feb 17, 2019 07:17 am ET

CLASS ACTION UPDATE for YOGA, IMMU, ALKS and ASTE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 15, 2019 10:50 pm ET

IMMUNOMEDICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Immunomedics, Inc. - IMMU

Feb 15, 2019 07:07 pm ET

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Immunomedics, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP alerts Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics”) investors that two securities fraud class action lawsuits have been filed in the United States District Court for the District of New Jersey (the “District of New Jersey”) against Immunomedics on behalf of purchasers of Immunomedics common stock between February 8, 2018 and January 18, 2019, inclusive (the “Class Period”).

Feb 15, 2019 03:42 pm ET

IMMU UPCOMING DEADLINE: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Important February 25th Deadline in Securities Class Action Lawsuit; Expanded Class Period – IMMU

Feb 15, 2019 11:43 am ET

CLASS ACTION UPDATE for IMMU, ASTE, SVXY and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 15, 2019 11:13 am ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of IMMU, YRIV, SVXY and UXIN

Feb 15, 2019 09:54 am ET

CLASS ACTION UPDATE for IMMU, DBVT, AXGN and MKL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 14, 2019 06:56 pm ET

Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Immunomedics, Inc. Investors

Feb 14, 2019 04:41 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunomedics, Inc. of Class Action Lawsuit and Upcoming Deadline – IMMU

Pomerantz LLP announces that a class action lawsuit has been filed against Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU) and certain of its officers and directors. The class action, filed in United States District Court,...

Feb 14, 2019 04:16 pm ET

CLASS ACTION UPDATE for XRAY, IMMU, ALKS and MAXR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 13, 2019 06:15 pm ET

CLASS ACTION UPDATE for IMMU, ATVI, GSM and MU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 13, 2019 03:27 pm ET

CLASS ACTION UPDATE for ARLO, IMMU, DBVT and YRIV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 13, 2019 02:22 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Immunomedics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ:IMMU) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class...

Feb 13, 2019 01:00 pm ET

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) and DXC Technology Company (DXC) and YRC Worldwide

Feb 13, 2019 10:19 am ET

CLASS ACTION UPDATE for YOGA, YRCW, IMMU and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 12, 2019 02:47 pm ET

CLASS ACTION UPDATE for ARLO, SOGO, IMMU and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 12, 2019 02:00 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SOGO, IMMU, AGN and W

Feb 12, 2019 10:41 am ET

CLASS ACTION UPDATE for IMMU, AXGN, MKL and MAXR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 12, 2019 10:22 am ET

February 25th Immunomedics Shareholder Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against Immunomedics, Inc. – IMMU

Feb 11, 2019 05:15 pm ET

Immunomedics Announces Oral Presentation at the 2019 Genitourinary Cancers Symposium

Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that updated data with longer follow-up on sacituzumab govitecan, its lead...

Feb 11, 2019 05:00 pm ET

CLASS ACTION UPDATE for IMMU, MKL, GSM and VALE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 11, 2019 01:58 pm ET

CLASS ACTION UPDATE for XPO, IMMU, DXC and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 11, 2019 11:03 am ET

CLASS ACTION UPDATE for IMMU, AGN, MAXR and MU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 11, 2019 07:25 am ET

Consolidated Research: 2019 Summary Expectations for Immunomedics, Allscripts Healthcare Solutions, Viper Energy Partners LP, Virtu Financial, FactSet Research, and MICT — Fundamental Analysis, Key Pe

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Immunomedics, Inc. (NASDAQ:IMMU), Allscripts Healthcare Solutions, Inc....

Feb 11, 2019 07:07 am ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of XRAY, IMMU, AXGN and ASTE

Feb 11, 2019 07:00 am ET

CLASS ACTION UPDATE for IMMU, AGN, MAXR and MU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 10, 2019 05:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NVIDIA, DXC Technology, Immunomedics, and Natural Health and Encourages Investors to Contact the Firm

Feb 08, 2019 10:50 pm ET

IMMUNOMEDICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Again

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 25, 2019 to file lead plaintiff applications in a securities class action lawsuit against...

Feb 08, 2019 05:48 pm ET

IMMU FEB. 25 DEADLINE ALERT: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Important Deadline in Case Seeking to Recover Investor Losses – IMMU

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Immunomedics, Inc. (NASDAQ: IMMU) from August 23, 2018 through December 20, 2018, inclusive (the “Class Period”) of the important February 25, 2019 lead...

Feb 08, 2019 03:53 pm ET

Pomerantz Law Firm Announces the Filing of a Class Action against Immunomedics, Inc. and Certain Officers – IMMU

Feb 08, 2019 02:58 pm ET

CLASS ACTION UPDATE for IMMU, AGN, MAXR and MU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 08, 2019 12:47 pm ET

CLASS ACTION UPDATE for IMMU, AXGN, ATVI and GSM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 08, 2019 11:00 am ET

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against JA Solar Holdings Co. Ltd. (JASO), Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) and DXC Technolo

Feb 08, 2019 10:19 am ET

CLASS ACTION UPDATE for SOGO, IMMU, NVDA and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 07, 2019 10:30 pm ET

Robbins Geller Rudman & Dowd LLP Announces a Securities Case Has Been Filed on Behalf of Purchasers of Immunomedics, Inc. Securities

Robbins Geller Rudman & Dowd LLP announces that a securities class action case has been filed on behalf of purchasers of Immunomedics, Inc. (NASDAQ:IMMU) common stock between August 23, 2018 and December 20, 2018 (the “Class Period”) in the U.S. District Court for the District of New Jersey, Odeh v. Immunomed

Feb 07, 2019 03:56 pm ET

February 25th Immunomedics Shareholder Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against Immunomedics, Inc. – IMMU

Feb 07, 2019 03:23 pm ET

CLASS ACTION UPDATE for WBT, SOGO, IMMU and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 07, 2019 01:56 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immunomedics Inc. – IMMU

Pomerantz LLP is investigating claims on behalf of investors of Immunomedics Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....

Feb 07, 2019 12:29 pm ET

CLASS ACTION UPDATE for TS, IMMU, NVDA and ATVI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 07, 2019 11:34 am ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of IMMU, PRGO, ALKS and MKL

Feb 06, 2019 03:09 pm ET

CLASS ACTION UPDATE for IMMU, PRGO, DXC and W: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 06, 2019 11:15 am ET

CLASS ACTION UPDATE for NSANY, XPO, IMMU and NVDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 06, 2019 09:56 am ET

XPO, AGN, IMMU: Block & Leviton LLP Reminds Shareholders of Important Deadlines

Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important deadlines listed below. If you have purchased or other acquired any of the securities listed below, you are...

Feb 06, 2019 07:30 am ET

Report: Developing Opportunities within United Technologies, Summit Hotel Properties, Immunomedics, PriceSmart, American Assets Trust, and Semtech — Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of United Technologies Corporation (NYSE:UTX), Summit Hotel Properties, Inc....

Feb 05, 2019 08:12 pm ET

CLASS ACTION UPDATE for TS, IMMU, GSM and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 05, 2019 12:15 pm ET

CLASS ACTION UPDATE for YRCW, IMMU, DXC and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 05, 2019 10:12 am ET

Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Immunomedics, Inc. Investors

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the District of New Jersey...

Feb 05, 2019 07:23 am ET

CLASS ACTION UPDATE for XRAY, IMMU, AGN and DXC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Feb 04, 2019 04:10 pm ET

SHAREHOLDER ALERT: GS IMMU DXC ALKS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Feb 04, 2019 03:27 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Immunomedics, Inc. To Contact The Firm

Feb 04, 2019 12:50 pm ET

INVESTOR DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunomedics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Feb 04, 2019 12:45 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of IMMU, PRGO, DXC and MU

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Feb 01, 2019 10:50 pm ET

IMMUNOMEDICS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Immunomedics, Inc. - IMMU

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 25, 2019 to file lead plaintiff applications in a securities class action lawsuit against Immunomedics, Inc. (NasdaqGM: IMMU), if they purchased the Company’s shares between August 23, 2018 and December 20, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.

Feb 01, 2019 04:00 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of XRAY, IMMU, AGN and DXC

Feb 01, 2019 02:00 pm ET

Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of YRCW, IMMU, PRGO and DXC

Feb 01, 2019 01:00 pm ET

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Immunomedics, Inc. (IMMU) and Lead Plaintiff Deadline: February 25, 2019

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Immunomedics, Inc. ("Immunomedics" or the "Company") (NASDAQ: IMMU) and certain of its officers, on behalf of...

Feb 01, 2019 10:14 am ET

Cohen Milstein Sellers & Toll PLLC Announces Investigation of Immunomedics, Inc.

Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Immunomedics, Inc. (“Immunomedics” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Feb 01, 2019 08:25 am ET

Factors of Influence in 2019, Key Indicators and Opportunity within Exelixis, Varian Medical, DXC Technology, Bridgepoint Education, Armstrong World Industries, and Immunomedics — New Research Emphasi

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Exelixis, Inc. (NASDAQ:EXEL), Varian Medical Systems, Inc. (NYSE:VAR), DXC...

Jan 31, 2019 09:10 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NVIDIA, DXC Technology, Immunomedics, and Natural Health and Encourages Investors to Contact the Firm

Jan 31, 2019 08:12 pm ET

CLASS ACTION UPDATE for DNKEY, YRCW, IMMU and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Jan 31, 2019 06:37 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immunomedics Inc. – IMMU

Jan 31, 2019 06:03 pm ET

IMMU CLASS ACTION ALERT: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Important Deadline in Securities Case Seeking to Recover Investor Losses – IMMU

Jan 31, 2019 04:00 pm ET

Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of LOMA, IMMU, DBVT and AXGN

Jan 31, 2019 11:45 am ET

SHAREHOLDER ALERT: WBT LOMA XPO IMMU: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Jan 30, 2019 06:33 pm ET

IMMUNOMEDICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Immunomedics, Inc. To Contact The Firm

NEW YORK, Jan. 30, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Immunomedics, Inc. ("Immunomedics" or the "Company") (NASDAQ:IMMU).

Jan 30, 2019 04:07 pm ET

CLASS ACTION UPDATE for XPO, IMMU, MAXR and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Jan 30, 2019 01:13 pm ET

Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against Immunomedics, Inc.

NEW YORK, Jan. 30, 2019 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against Immunomedics, Inc. ("Immunomedics" or the "Company") (NASDAQ: IMMU) and other defendants, related to alleged violations of federal securities laws. If you purchased Immunomedics securities between August 23, 2018 and December 20, 2018, you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for more information. The lead plaintiff deadline is February 25,

Jan 30, 2019 11:45 am ET

Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of YOGA, TS, IMMU and NVDA

Jan 30, 2019 09:23 am ET

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Immunomedics, Inc. – IMMU

Jan 29, 2019 08:07 pm ET

SHAREHOLDER ALERT: IMMU PRGO AXGN W: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Jan 29, 2019 02:03 pm ET

SHAREHOLDER ALERT: XPO XRAY IMMU DXC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Jan 29, 2019 10:20 am ET

INVESTOR NOTICE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunomedics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Jan 28, 2019 04:09 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NSANY, APHA, CURO and IMMU

Jan 28, 2019 12:05 pm ET

CLASS ACTION UPDATE for XRAY, IMMU and SNAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Jan 25, 2019 09:50 pm ET

IMMUNOMEDICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Immunomedics, Inc. - IMMU

NEW ORLEANS, Jan. 25, 2019 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 25, 2019 to file lead plaintiff applications in a securities class action lawsuit against Immunomedics, Inc. (NasdaqGM: IMMU), if they purchased the Company's shares between August 23, 2018 and December 20, 2018, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of New Jersey.

Jan 25, 2019 08:01 pm ET

IMMU CLASS ACTION: Rosen Law Firm Announces Securities Class Action Lawsuit Against Immunomedics, Inc. - IMMU

NEW YORK, Jan. 25, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a lawsuit on behalf of purchasers of the securities of Immunomedics, Inc. (NASDAQ: IMMU) from August 23, 2018 through December 20, 2018, inclusive (the "Class Period"). The firm reminds investors of the important February 25, 2019 lead plaintiff deadline in the class action.

You are here

(:IMMU)

Business Focus: N/A